Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 7.30p
   
  • Change Today:
      0.000p
  • 52 Week High: 7.70
  • 52 Week Low: 3.88
  • Currency: UK Pounds
  • Shares Issued: 4,766.44m
  • Volume: 0
  • Market Cap: £347.95m
  • RiskGrade: 268

AGY Overview

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our vaccines are aluminium free. Driving convenience; our ultra-short course treatments make life easier and increase adherence.

Key Personnel

CEO: Manuel Llobet
Chief Finance Officer: Shaun Furlong
Independent Non-Executive Director: Tunde Otulana
Non-Executive Chairman: Peter Jensen
Non-Executive Dir: Zheqing Shen , Cheryl MacDiarmid, David Ball, Anthony Parker

Contact Details

Address: Dominion Way, Worthing, West Sussex, United Kingdom, BN14 8SA
Phone: +44 (0) 1903 844 700
Fax: +44 (0) 1903 844 726
Website: http://www.allergytherapeutics.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00B02LCQ05

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AGY Market Data

Currency UK Pounds
Share Price 7.30p
Change Today 0.000p
% Change 0.00 %
52 Week High 7.70
52 Week Low 3.88
Volume 0
Shares Issued 4,766.44m
Market Cap £347.95m
RiskGrade 268

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
68.64% below the market average68.64% below the market average68.64% below the market average68.64% below the market average68.64% below the market average
60.87% below the sector average60.87% below the sector average60.87% below the sector average60.87% below the sector average60.87% below the sector average
Price Trend
87.95% above the market average87.95% above the market average87.95% above the market average87.95% above the market average87.95% above the market average
95.65% above the sector average95.65% above the sector average95.65% above the sector average95.65% above the sector average95.65% above the sector average
Income Not Available
Growth
54.09% below the market average54.09% below the market average54.09% below the market average54.09% below the market average54.09% below the market average
67.74% below the sector average67.74% below the sector average67.74% below the sector average67.74% below the sector average67.74% below the sector average

AGY Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

AGY Key Personnel

CEO Manuel Llobet

Top of Page